Pharmaceutical Product Monograph: Enoxaparin Sodium Injection (60 mg / 0.6 mL)
In the pharmaceutical industry, Enoxaparin is a Low Molecular Weight Heparin (LMWH). As a pharmacist and manufacturer, I view this molecule as a “Precision Anticoagulant”—it is technically designed to be a fragmented version of heparin with a more predictable pharmacokinetic profile, higher bioavailability, and a lower risk of bleeding complications.
At your WHO-GMP facility in Mumbai, the 60 mg strength (0.6 mL) is a high-demand SKU for Cardiology, Orthopedics, and Critical Care portfolios. It is primarily used for the treatment and prophylaxis of thromboembolic disorders (blood clots).
Therapeutic Profile: Primary Indications
The 60 mg dose is a “treatment-grade” strength, typically used based on the patient’s body weight (usually $1 \text{ mg/kg}$ twice daily or $1.5 \text{ mg/kg}$ once daily).
| Indication | Clinical Context | Technical Rationale |
| DVT & Pulmonary Embolism | Acute Treatment | Used to treat existing Deep Vein Thrombosis (DVT) with or without Pulmonary Embolism (PE). |
| Unstable Angina & NSTEMI | Cardiology | Prevents further clot formation in the coronary arteries during an acute cardiac event (Heart Attack). |
| Acute STEMI | Emergency Medicine | Used alongside thrombolytic drugs to maintain vessel patency after a major heart attack. |
| Bariatric Prophylaxis | Surgery | Higher 60 mg doses are often required for clot prevention in high-risk, obese patients undergoing major surgery. |
| Bridging Therapy | Peri-operative | Used to maintain anticoagulation in patients who must temporarily stop oral Warfarin for surgery. |
Mechanism: Factor Xa Inhibition
Enoxaparin works by sabotaging the “Coagulation Cascade” that leads to clot formation:
Antithrombin III Binding: Enoxaparin binds to and accelerates the activity of Antithrombin III, a natural anticoagulant in the blood.
Factor Xa Specificity: Technically, Enoxaparin has a very high ratio of Anti-Factor Xa activity to Anti-Factor IIa (Thrombin) activity (roughly 3:1 to 5:1).
Clot Prevention: By neutralizing Factor Xa, it prevents the conversion of Prothrombin to Thrombin, effectively stopping the formation of a stable fibrin clot.
The Pharmacist’s “Technical Warning”
The “PFS” Administration: As a pharmacist, I must emphasize that Enoxaparin must be given by Subcutaneous (SC) injection into the abdominal wall (the “love handles”). It must NEVER be given by Intramuscular (IM) injection as it will cause a massive hematoma (bruising).
The “Air Bubble” Rule: In your Prefilled Syringes (PFS), there is a small nitrogen air bubble. As a manufacturer, I advise B2B clients to tell nurses not to expel the air bubble before injection; it is technically designed to “clear” the needle and prevent the drug from leaking into the skin.
Renal Adjustment: Enoxaparin is cleared by the kidneys. For patients with severe renal impairment ($CrCl < 30 \text{ mL/min}$), the dose must be strictly reduced to 30 mg.
HIT Risk: While lower than with Heparin, there is still a technical risk of Heparin-Induced Thrombocytopenia (HIT). Platelet counts should be monitored.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Biological Origin” USP: On your digital marketplace, highlight that your Enoxaparin is derived from Porcine Intestinal Mucosa. Ensuring a “Prion-Free” and high-purity source is a major technical benchmark for European and American B2B buyers.
The “Anti-Xa Assay” Quality: In your COA (Certificate of Analysis), emphasize your Anti-Xa Potency Testing. International tenders require strict adherence to USP/EP standards for potency ($100 \text{ IU per mg}$ of anti-Xa activity).
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Enoxaparin 20 mg, 40 mg, 60 mg, and 80 mg PFS to support your registration in international B2B hospital and cardiology tenders.